The pace of hepatitis C virus (HCV) drug development in recent years has accelerated
dramatically. For patients to benefit from these impressive advances, practitioners need …

Recent evidence has been accumulated showing that anti‐HCV‐positive serologic status is
significantly associated with lower survival in dialysis populations, but the mechanisms …

The availability of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV)
infection has resulted in a profound shift in the approach to the management of this infection …

Background: Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection
in kidney transplant recipients is limited because of the risk for allograft rejection and poor …

This current version provides a summary of recommen-dations for best practice in creating
peritoneal access for patients on peritoneal dialysis (PD). A more detailed review of …

Background. The impact of dialysis modality on the rates and types of infectious
complications has not been well studied. The aim of the present investigation was to …

Hepatitis C virus (HCV) is both hepatotrophic and lymphotropic virus that causes liver as
well extrahepatic manifestations including cryoglobulinemic vasculitis, the most frequent and …

Recent evidence has shown that anti‐HCV‐positive serologic status is significantly linked to
lower patient and graft survival after renal transplant, but conflicting results have been given …

Hepatitis C virus (HCV) infection is more prevalent and is associated with higher mortality in
patients receiving dialysis and in kidney transplant recipients than in the general population …

Hepatitis E virus (HEV) can induce chronic hepatitis in immunosuppressed patients. There is
no established treatment for HEV infection. Pegylated interferon-alpha-2a (Peg-IFN-α-2a) …